Filing Flows › Organon (OGN) › Q3 2026 › vs Q2 2026
Organon (OGN) Q3 2026 vs Q2 2026 (quarter over quarter)
Organon's revenue rose $16.0M (+1%) from $1.6B in Q2 2026 to $1.6B in Q3 2026. Gross margin 55.2% against 54.4% (+0.8 pts).
Organon, Q3 2026: revenue $1.6B (-2% year over year), operating margin 16.2%, net earnings $164M, operating cash flow $370M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 55.2% | 54.4% | +0.8 pts |
| Operating margin | 16.2% | 11.7% | +4.5 pts |
| Net margin | 10.4% | 6.9% | +3.5 pts |
| Free cash flow margin | 20.7% | 4.2% | +16.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $16.0M | +1% |
| Gross profit | $869M | $847M | $22.0M | +3% |
| Cost of revenue | $705M | $711M | −$6.0M | -0.8% |
| Operating profit | $255M | $183M | $72.0M | +39% |
| Operating expenses | $614M | $664M | −$50.0M | -8% |
| Pre-tax earnings | $255M | $183M | $72.0M | +39% |
| Research & development | $83.0M | $90.0M | −$7.0M | -8% |
| SG&A | $421M | $434M | −$13.0M | -3% |
| Other operating costs | $110M | $140M | −$30.0M | -21% |
| Net earnings | $164M | $108M | $56.0M | +52% |
| Income tax | $91.0M | $75.0M | $16.0M | +21% |
| Depreciation | $34.0M | $34.0M | $0 | 0% |
| Share-based compensation | $21.0M | $25.0M | −$4.0M | -16% |
| Working capital & other | $151M | −$60.0M | $211M | — |
| Operating cash flow | $370M | $107M | $263M | +246% |
| Free cash flow (OCF − capex) | $326M | $65.0M | $261M | +402% |
| Capital expenditures | $44.0M | $42.0M | $2.0M | +5% |
Questions
How much did Organon's revenue grow quarter over quarter in Q3 2026?
Organon's revenue rose $16.0M (+1%) from $1.6B in Q2 2026 to $1.6B in Q3 2026. Gross margin 55.2% against 54.4% (+0.8 pts).